<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131137">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915277</url>
  </required_header>
  <id_info>
    <org_study_id>PHN-DEX</org_study_id>
    <nct_id>NCT01915277</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase I study is to determine the safety of a drug called
      dexmedetomidine (DEX) as part of a balanced general anesthetic and sedative strategy for
      neonates and infants undergoing corrective cardiac surgery that requires the use of
      cardiopulmonary bypass for congenital cardiac problems. This study will also design and
      validate a dosing schema for the use of DEX as described above.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The occurrence of a safety event that is possibly, probably or definitely related to DEX administration</measure>
    <time_frame>Within 4 hours after DEX adminstration</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The occurrence of any of the following that is possibly, probably, or definitely related to DEX administration:
Bradycardia
Heart block
Junctional rhythm
Hypotension
Excessive sedation
Cardiac arrest or ECMO cannulation
Serious Adverse Event (SAE)
Both the DEX dose, and DEX exposure will be assessed for associations with the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of DEX</measure>
    <time_frame>Intraoperatively and up to 36 hours post-operatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentrations of dex obtained intraoperatively and up to 36 hours post-operatively will be used to create drug dosing models.  These models will then be evaluated to determine how effective they are at achieving targeted plasma concentration levels.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Transposition of the Great Arteries</condition>
  <condition>Tetralogy of Fallot</condition>
  <condition>Ventricular Septal Defect</condition>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neonate dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neonate dexmedetomidine dosing cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant dosing cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant dexmedetomidine dosing cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>Neonate dosing cohort 1</arm_group_label>
    <arm_group_label>Neonate dosing cohort 2</arm_group_label>
    <arm_group_label>Neonate dosing cohort 3</arm_group_label>
    <arm_group_label>Neonate dosing cohort 4</arm_group_label>
    <arm_group_label>Neonate dosing cohort 5</arm_group_label>
    <arm_group_label>Infant dosing cohort 1</arm_group_label>
    <arm_group_label>Infant dosing cohort 2</arm_group_label>
    <arm_group_label>Infant dosing cohort 3</arm_group_label>
    <arm_group_label>Infant dosing cohort 4</arm_group_label>
    <arm_group_label>Infant dosing cohort 5</arm_group_label>
    <other_name>Precedex, dexmedetomidine HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 0 to 90 days.

          -  Diagnosis of: D-transposition of the great arteries (with or without ventricular
             septal defect), or tetralogy of Fallot, or ventricular septal defect (with or without
             associated atrial septal defect and/or patent ductus arteriosus)

          -  Scheduled for complete corrective two-ventricle surgical repair with cardiopulmonary
             bypass.

        Exclusion Criteria:

          -  Less than 37 completed weeks' gestational age at birth.

          -  Known or suspected hepatic dysfunction; AST and ALT &gt;3X upper limit of normal at the
             time of screening within 72 hours of operation.

          -  Known or suspected renal dysfunction; serum creatinine &gt; 0.8 mg/dL within 72 hours of
             operation.

          -  Preoperative administration of DEX or clonidine within 72 hours of operation.

          -  Major congenital anomaly(ies) outside the cardiovascular system.

          -  Preoperative central nervous system injury resulting in clinical signs and symptoms:
             coma, seizures, hemiparesis.

          -  Planned period of deep hypothermic circulatory arrest.

          -  History of second or third degree heart block.

          -  Sinus or junctional bradycardia below 80 BPM sustained for greater than 15 minutes
             within 72 hours of operation.

          -  Junctional rhythm sustained for greater than 15 minutes within 72 hours of operation.

          -  Hypotension defined as mean arterial blood pressure below 35 mm Hg for 0-21 day old
             neonatal patients, and below 40 mm Hg for 22- 90 day old infant patients sustained
             for greater than 15 minutes within 72 hours of operation.

          -  History of cardiac arrest or ECMO cannulation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean B Andropoulos, MD</last_name>
      <phone>832-826-5822</phone>
      <email>dbandrop@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Dean B Andropoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric corrective cardiac surgery</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Septal Defects, Ventricular</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
